Dr. Lal Path Labs has acquired a 70% stake in SN Genelab Private Limited for up to ₹168 crore, with an additional performance-linked earn-out of up to ₹31.5 crore. The transaction, approved by the board on September 24, 2026, will make SN Gene a subsidiary of the company.

Deal structure and timeline

The acquisition involves a majority stake purchase from existing shareholders. The total consideration is structured as a primary cash payment of up to ₹168 crore and an earn-out component capped at ₹31.5 crore. The company stated that the transaction is expected to be completed by November 30, 2026. No governmental or regulatory approvals are required for the deal.

Strategic rationale and target profile

The primary objective of the acquisition is to strengthen Dr. Lal PathLabs' expertise in genomics and broaden its portfolio of advanced diagnostic services. SN Genelab Private Limited was incorporated on December 16, 2013, in Gujarat and operates in the diagnostics-genomics sector. The disclosure confirms that the proposed acquisition does not fall within the ambit of related party transactions.

Financials of the target entity

SN Genelab has shown consistent revenue growth over the last three fiscal years. The target's turnover increased from ₹43.27 crore in FY24 to ₹57.96 crore in FY26. This growth trajectory supports the strategic value of the acquisition for expanding the parent company's high-margin diagnostic capabilities.

What the numbers show

The acquisition price implies a significant premium relative to the target's current revenue base. With a primary consideration of ₹168 crore for a 70% stake, the implied enterprise value for 100% of SN Genelab exceeds ₹240 crore. Against FY26 turnover of ₹57.96 crore, this suggests a valuation multiple of approximately 4.1x revenue. The earn-out structure of up to ₹31.5 crore further aligns the seller's incentives with future performance, potentially raising the total cost to over ₹280 crore for full ownership if targets are met.

Dr. Lal PathLabs Limited has completed the subscription of a 30% stake in Neuome Technologies Private Limited through its wholly owned subsidiary, Dr. Lal Ventures Private Limited.

The transaction was finalized on August 27, 2026, in accordance with the terms and conditions of the agreement. This move establishes Neuome as an associate company of Dr. Lal PathLabs.

Transaction Details

The Board of Directors of Dr. Lal Ventures had previously approved the stake acquisition in an intimation dated July 24, 2026. The company confirmed that the subscription process concluded on August 27, 2026.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, regarding the required intimations.

All necessary disclosures related to this corporate action were included in the earlier communication issued on July 24, 2026. The company requested stock exchanges to record the completion of the transaction.